» Articles » PMID: 7348574

Oestrogen Receptor Concentration in Primary Breast Cancer and Axillary Node Metastases

Overview
Specialty Oncology
Date 1981 Jan 1
PMID 7348574
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The primary tumour and 1-3 invaded, axillary nodes from each of 24 patients were examined both histologically for the proportion of the specimen constituted by malignant epithelial cells ('cellularity index') and biochemically for oestrogen receptor concentration. Both malignant epithelial cell content and oestrogen receptor concentration were significantly higher in the nodal metastases than in the primary tumours, malignant cells constituting approximately half of the former tissue and three quarters of the latter. On average, receptor concentrations were 1.6 x (protein basis) to 2.3 x (wet weight basis) higher in nodes than in the primary tumours, probably due at least in part to the difference in cellularity. When, to eliminate the effect of the latter, receptor concentration in each tumour deposit was 'corrected' using the appropriate 'cellularity index', the difference in receptor concentration between primary and node was significantly diminished, but not quite eliminated. In one patient, progestogen receptor concentrations were also studied and found to be higher in the nodes than in the primary tumour. If the actual quantity of receptor is to be used for predictive/prognostic purposes, then either a different 'cut-off point' should be used for invaded nodes from that used for assessment on the primary tumour, or receptor concentrations should be corrected for differences in cellularity.

Citing Articles

Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.

Yao Z, Lu L, Wang R, Jin L, Liu S, Li H Med Oncol. 2013; 31(1):798.

PMID: 24307349 DOI: 10.1007/s12032-013-0798-y.


Prospective evaluation of prognostic factors in operable breast cancer.

Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J Br J Cancer. 1996; 74(9):1469-78.

PMID: 8912547 PMC: 2074769. DOI: 10.1038/bjc.1996.567.


Cellularity and the quantitation of estrogen receptors.

Mason R, Steele R, Hawkins R, Miller W, Forrest A Breast Cancer Res Treat. 1982; 2(3):239-42.

PMID: 7150778 DOI: 10.1007/BF01806936.


Prostaglandins in human mammary cancer.

Watson D, Kelly R, Hawkins R, Miller W Br J Cancer. 1984; 49(4):459-64.

PMID: 6585216 PMC: 1976779. DOI: 10.1038/bjc.1984.73.


The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas.

Hahnel R, Twaddle E Breast Cancer Res Treat. 1985; 5(2):155-63.

PMID: 4016281 DOI: 10.1007/BF01805989.


References
1.
Hawkins R, Roberts M, Forrest A . Oestrogen receptors and breast cancer: current status. Br J Surg. 1980; 67(3):153-69. DOI: 10.1002/bjs.1800670302. View

2.
Kiang D, Kennedy B, Snover D . Biological and histological characteristics of simultaneous bilateral breast cancer. Lancet. 1980; 2(8204):1105-7. DOI: 10.1016/s0140-6736(80)92541-6. View

3.
Parl F, Wagner R . The histopathological evaluation of human breast cancers in correlation with estrogen receptor values. Cancer. 1980; 46(2):362-7. DOI: 10.1002/1097-0142(19800715)46:2<362::aid-cncr2820460225>3.0.co;2-z. View

4.
WALT A, Singhakowinta A, Brooks S, Cortez A . The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery. 1976; 80(4):506-12. View

5.
Leclercq G, HEUSON J . Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer. Eur J Cancer (1965). 1977; 13(11):1205-15. DOI: 10.1016/0014-2964(77)90026-3. View